Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sugi Holdings Co.,Ltd. (7649.T)
JPY3,178.00
-109.00 (-3.32%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
62-1 Shine Yokonemachi 474-0011
Obu, JP
Obu, JP
CEO
Katsunori Sugiura
Website
sugi-hd.co.jp
IPO
2001-07-26
ISIN JP3397060009
Also trades on
Other OTC · SGIPF (USD)
Tokyo Stock Exchange · 7649.T (JPY)
Description
Headquartered in Obu, Japan, Sugi Holdings Co.,Ltd. was established in 1976. This Japanese enterprise primarily operates a network of drugstores across the country. In addition to its retail activities, the company extends its offerings to include visiting nursing services and home care support. By June 1, 2019, Sugi Holdings had expanded its store count to 1,190 locations.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY3,178.00
-109.00 (-3.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
778.5K
Beta
0.32
Float Shares
99.39M
Free Float %
54.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.56% | -4.08% | -12.06% | -23.33% | -25.33% | -24.90% | -13.12% | +41.15% | -4.21% | +45.38% | +482.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,178.00
DCF (Unlevered)
3,723.02
+17.1%
DCF (Levered)
3,797.15
+19.5%
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.59
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +9.5%+17.9% ★ Q1'26: +6.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +18.1%+16.9% Q1'26: +40.6% (vs Q1'25)
-
FCF margin Medical - Pharmaceuticals: +29.9%+1.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +4.8%+4.4% Q1'26: +5.5% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.0%+10.4% ★ Q1'26: +16.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: -0.1%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Medical - Pharmaceuticals: -0.11×0.85× ★ Q1'26: 1.20× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Feb 2015 actual |
Feb 2016 actual |
Feb 2017 actual |
Feb 2018 actual |
Feb 2019 actual |
Feb 2020 actual |
Feb 2021 actual |
Feb 2022 actual |
Feb 2023 actual |
Feb 2024 actual |
Feb 2025 actual |
Feb 2026 8 Rev. Ana. 8 EPS Ana. |
Feb 2027 7 Rev. Ana. 6 EPS Ana. |
Feb 2028 7 Rev. Ana. 7 EPS Ana. |
Feb 2029 3 Rev. Ana. 3 EPS Ana. |
Feb 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
383.64B
est: 384.43B (-0.2%)
|
414.89B
est: 411.94B (+0.7%)
|
430.80B
est: 430.98B (0.0%)
|
457.05B
est: 453.63B (+0.8%)
|
488.46B
est: 487.38B (+0.2%)
|
541.96B
est: 535.48B (+1.2%)
|
602.51B
est: 600.20B (+0.4%)
|
625.48B
est: 626.49B (-0.2%)
|
667.65B
est: 668.27B (-0.1%)
|
744.48B
est: 767.59B (-3.0%)
|
878.02B
est: 873.35B (+0.5%)
|
1.01T
1.00T – 1.02T
+15.5% YoY
|
1.10T
1.08T – 1.13T
+9.0% YoY
|
1.20T
1.17T – 1.29T
+9.1% YoY
|
1.27T
1.25T – 1.30T
+6.2% YoY
|
1.27T
1.24T – 1.33T
-0.6% YoY
|
| EBITDA |
25.86B
est: 24.42B (+5.9%)
|
28.12B
est: 26.17B (+7.4%)
|
28.15B
est: 27.38B (+2.8%)
|
31.04B
est: 28.82B (+7.7%)
|
33.47B
est: 30.96B (+8.1%)
|
38.36B
est: 34.02B (+12.8%)
|
41.48B
est: 38.13B (+8.8%)
|
38.74B
est: 39.80B (-2.7%)
|
40.56B
est: 42.45B (-4.5%)
|
46.24B
est: 48.63B (-4.9%)
|
56.18B
est: 55.33B (+1.5%)
|
63.91B
63.38B – 64.56B
+15.5% YoY
|
69.67B
68.52B – 71.36B
+9.0% YoY
|
76.04B
73.88B – 81.77B
+9.1% YoY
|
80.72B
79.26B – 82.18B
+6.2% YoY
|
80.26B
78.43B – 84.32B
-0.6% YoY
|
| EBIT |
20.91B
est: 17.32B (+20.7%)
|
22.85B
est: 18.56B (+23.1%)
|
22.55B
est: 19.42B (+16.1%)
|
24.58B
est: 20.44B (+20.3%)
|
26.08B
est: 21.96B (+18.8%)
|
29.95B
est: 24.13B (+24.1%)
|
31.54B
est: 27.04B (+16.6%)
|
27.47B
est: 28.23B (-2.7%)
|
28.20B
est: 30.11B (-6.3%)
|
32.12B
est: 33.93B (-5.3%)
|
38.31B
est: 38.60B (-0.8%)
|
44.59B
44.22B – 45.05B
+15.5% YoY
|
48.61B
47.81B – 49.79B
+9.0% YoY
|
53.06B
51.54B – 57.05B
+9.1% YoY
|
56.32B
55.30B – 57.34B
+6.2% YoY
|
55.99B
54.72B – 58.83B
-0.6% YoY
|
| Net Income |
12.86B
est: 12.51B (+2.8%)
|
14.61B
est: 14.19B (+2.9%)
|
14.95B
est: 13.40B (+11.5%)
|
16.41B
est: 15.10B (+8.7%)
|
17.94B
est: 15.81B (+13.5%)
|
20.78B
est: 18.44B (+12.7%)
|
21.12B
est: 21.64B (-2.4%)
|
19.39B
est: 18.70B (+3.7%)
|
19.01B
est: 18.69B (+1.7%)
|
21.98B
est: 22.54B (-2.5%)
|
25.69B
est: 26.27B (-2.2%)
|
44.98B
43.51B – 46.82B
+71.2% YoY
|
33.35B
31.61B – 35.41B
-25.9% YoY
|
36.81B
34.83B – 39.11B
+10.4% YoY
|
40.13B
36.79B – 41.15B
+9.0% YoY
|
44.54B
43.22B – 47.47B
+11.0% YoY
|
| SGA |
84.76B
est: 98.31B (-13.8%)
|
92.60B
est: 105.34B (-12.1%)
|
97.18B
est: 110.21B (-11.8%)
|
106.80B
est: 116.00B (-7.9%)
|
116.48B
est: 124.64B (-6.5%)
|
132.42B
est: 136.94B (-3.3%)
|
147.59B
est: 153.49B (-3.8%)
|
159.35B
est: 160.21B (-0.5%)
|
170.87B
est: 170.89B (0.0%)
|
192.22B
est: 200.11B (-3.9%)
|
232.48B
est: 227.68B (+2.1%)
|
262.98B
260.82B – 265.69B
+15.5% YoY
|
286.71B
281.96B – 293.66B
+9.0% YoY
|
312.93B
304.01B – 336.49B
+9.1% YoY
|
332.18B
326.17B – 338.20B
+6.2% YoY
|
330.27B
322.76B – 347.00B
-0.6% YoY
|
| EPS |
67.71
est: 69.15 (-2.1%)
|
76.89
est: 78.43 (-2.0%)
|
78.69
est: 74.06 (+6.2%)
|
86.40
est: 83.44 (+3.5%)
|
95.91
est: 87.34 (+9.8%)
|
112.07
est: 101.89 (+10.0%)
|
113.89
est: 119.57 (-4.7%)
|
104.56
est: 103.34 (+1.2%)
|
103.82
est: 103.27 (+0.5%)
|
121.46
est: 124.55 (-2.5%)
|
141.96
est: 142.57 (-0.4%)
|
247.24
240.45 – 258.71
+73.4% YoY
|
185.22
174.65 – 195.66
-25.1% YoY
|
205.10
192.48 – 216.13
+10.7% YoY
|
218.21
203.27 – 227.41
+6.4% YoY
|
246.10
238.83 – 262.31
+12.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-10 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
19.66B
OE per share TTM
108.63
Owner's Yield
3.95%
Maintenance CapEx ratio
76.90%
Maint CapEx / Avg PPE
13.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
5.57M
Shares Outstanding
180.97M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Katsunori Sugiura | President & Representative Director | — | male |
| Makoto Kasai | Executive Managing Officer & CFO | — | male |
| Mari Konagaya | Executive Managing Officer & GM of Legal Affairs Department | — | — |
| Shigeki Mori | Executive Managing Officer & Chief HR Officer | — | — |
| Shinya Sugiura | Executive Vice President & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7649.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
